Comparative Analysis of C-Reactive Protein and Procalcitonin Levels in the Severity of COVID-19 Patients
DOI:
https://doi.org/10.24293/ijcpml.v30i2.2156Keywords:
Severity of COVID-19, CRP, procalcitoninAbstract
Coronavirus Disease 2019 (COVID-19) is a systemic disease characterized by mild to critical symptoms with a high risk of mortality. Fast and precise inflammatory markers are needed to predict the severity and prognosis of COVID-19 to decrease the mortality rate. The elevated levels of C-Reactive Protein (CRP) and procalcitonin may predict an increased risk of aggravation in COVID-19 patients. This study aimed to analyze the CRP and procalcitonin levels of COVID-19 severity. This was a cross-sectional retrospective study involving 160 COVID-19 patients at Dr. Wahidin Sudirohusodo Hospital. Subjects were grouped based on the severity of COVID-19 (mild, moderate, severe, critical). The difference in CRP and procalcitonin levels based on the severity of COVID-19 was analyzed using the Kruskal-Wallis test and the Spearman correlation test. The age of participants in this study ranged from 19-87 years old. The higher CRP and procalcitonin level shows heavier the severity of COVID-19 (p<0.001). This indicated a significant difference between CRP, procalcitonin levels, and the severity of COVID-19. This study showed that there was a significant correlation between CRP and procalcitonin with the severity of COVID-19, CRP (p<0.001) and procalcitonin (p<0.001).
Downloads
References
Bchetnia M, Girard C, Duchaine C, Laprise C. The outbreak of the novel severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2): A review of the current global status. J Infect Public Health, 2020; 13(11): 1601-1610.
World Health Organization. WHO Coronavirus Disease (COVID-19) dashboard with vaccination data | WHO Coronavirus (COVID-19) dashboard with vaccination data. World Health Organization, 2021; 1–5.
Kemenkes RI. Pedoman tatalaksana COVID-19. 2022; 1–112.
Ali N. Elevated level of C-reactive protein may be an early marker to predict risk for severity of COVID-19. Journal of Medical Virology, 2020; 92(11): 2409-2411.
Liu ZM, Li JP, Wang SP, Chen DY, Zeng W, et al. Association of procalcitonin levels with the progression and prognosis of hospitalized patients with COVID-19. Internat J Med Sci, 2020; 17(16): 2468-76.
Hu R, Han C, Pei S, Yin M, Chen X. Procalcitonin levels in COVID-19 patients. Internat J Antimicrob Agents, 2020; 56(2): 106051.
Lippi G, Plebani M. Procalcitonin in patients with severe Coronavirus Disease 2019 (COVID-19): A meta-analysis. Clin Chim Acta, 2020; 505: 190–191.
Zhu J, Ji P, Pang J, Zhong Z, Li H, et al. Clinical characteristics of 3062 COVID-19 patients: A meta-analysis. Journal of Medical Virology, 2020; 92(10): 1902-1914.
Kragholm K, Andersen MP, Gerds TA, Butt JH, Østergaard L, et al. Association between male sex and outcomes of Coronavirus Disease 2019 (COVID-19) – a Danish nationwide, register-based study. Clinical Infectious Diseases, 2021; 73(11): e4025-e4030.
Jiang F, Deng L, Zhang L, Cai Y, Cheung CW, Xia Z. Review of the clinical characteristics of Coronavirus Disease 2019 (COVID-19). Journal of General Internal Medicine, 2020; 35(5): 1545-1549.
Liu F, Li L, Xu M Da, Wu J, Luo D, et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. J Clin Virol, 2020; 127: 104370
Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan China. Intensive Care Medicine, 2020; 46(5): 846-848.
Muhammad Sheshe S, Muhammad Labbo A, Garba Mohammed K, Sheshe S, Nazifi A, et al. Mechanism of antiviral immune response and COVID-19 infection. Asian J Immunol, 2020; 3(3): 1–8.
Shen Y, Cheng C, Zheng X, Jin Y, Duan G, et al. Elevated procalcitonin is positively associated with the severity of COVID-19: A meta-analysis based on 10 cohort studies. Medicina, 2021; 57(6): 594.
Boechat JL, Wandalsen GF, Kuschnir FC, Delgado L. COVID-19, and pediatric asthma: Clinical and management challenges. International Journal of Environmental Research and Public Health, 2021; 18(3): 1093.
Torres Acosta MA, Singer BD. Pathogenesis of COVID-19-induced ARDS: Implications for an ageing population. Eur Respir J. 2020; 56: 2002049.
Gautam S, Cohen AJ, Stahl Y, Valda Toro P, Young GM, et al. Severe respiratory viral infection induces procalcitonin in the absence of bacterial pneumonia. Thorax, 2020; 75(11): 974–81.
Gulhar R, Ashraf MA, Jialal I. Physiology, acute phase reactants. Publishing, 2023. Available from:https://www.ncbi.nlm.nih.gov/books/NBK519570/(accessed April 24, 2023).
Lugito NPH. Is procalcitonin a part of human immunological response to SARS-CoV-2 infection or just a marker of bacterial coinfection?. Curr Res Transl Med, 2021; 69(2): 10328
Downloads
Submitted
Accepted
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
